Royalty Pharma plc financial data

Symbol
RPRX on Nasdaq
Location
110 East 59 Th Street, New York, NY
State of incorporation
United Kingdom
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.04K % +353%
Return On Equity 6.85 % +166%
Return On Assets 4.08 % +174%
Operating Margin 42.9 % +132%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 13.7B USD -25.9%
Weighted Average Number of Shares Outstanding, Basic 451M shares +0.14%
Weighted Average Number of Shares Outstanding, Diluted 597M shares -1.48%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.24B USD -5.24%
Research and Development Expense 52M USD -32.5%
General and Administrative Expense 229M USD -11.1%
Costs and Expenses 1.28B USD -33.6%
Operating Income (Loss) 960M USD +120%
Nonoperating Income (Expense) 69.6M USD +108%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 1.03B USD +119%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent 673M USD +164%
Earnings Per Share, Basic 1.51 USD/shares +175%
Earnings Per Share, Diluted 1.51 USD/shares +180%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.76B USD -18.8%
Other Assets, Current 2.29M USD -77.6%
Assets, Current 2.58B USD -12.7%
Other Assets, Noncurrent 27.6M USD -6.3%
Assets 17.7B USD +3.13%
Liabilities, Current 276M USD -76.5%
Other Liabilities, Noncurrent 27M USD
Liabilities 7.9B USD +8.17%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD -100%
Retained Earnings (Accumulated Deficit) 2.38B USD +5.56%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 9.75B USD -0.63%
Liabilities and Equity 17.7B USD +3.13%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 665M USD -35.7%
Net Cash Provided by (Used in) Financing Activities -212M USD -0.77%
Net Cash Provided by (Used in) Investing Activities -86.7M USD +84.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 366M USD +38.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.76B USD -18.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 79M USD -4.38%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 1.13B USD +4401%
Additional Paid in Capital 4.1B USD +1.72%
Amortization of Intangible Assets 0 USD -100%
Share-based Payment Arrangement, Expense 2.9M USD -22.2%
Interest Expense 184M USD -1.8%